is non-small cell lung cancer (NSCLC). For the majority of patients, lost the chance of radical operation or radiotherapy, chemotherapy is the main treatment. However, because of the diversities of tumor behavior and drug-resistant, the chemotherapy of advanced NSCLC is not optimistic. In recent years, with the application of molecular markers for individual chemotherapy, these patients have achieved prolong life and improved life quality. Individualized chemotherapy based on molecular markers to select the appropriate drug is the problem that needs to be solved. The paper gives a brief review on the role of ribonucleotide reductase subunit 1 (RRM1) in the treatment and prognosis of advanced NSCLC. Individualized chemotherapy by RRM1 can't become commonplace for advanced NSCLC and needs further research.
。Zhang等 [19] 就通过其前瞻性研
E RCC+R R M1-T U BB 3 -（G e m+Ta x）、E RCC+R R M1-www.lungca.org www.lungca.org Protein level [19] ERCC1, The response rates in the Gem+P, Doc+P and vinorelbine+P groups were 42.9%, 36.7% and 27.9%, respectively (P=0.568). The PFS was 5.6, 5.0 mo, 4.8 mo (P=0.975), respectively, and the OS was 12.5 mo, 11.0 mo, 9.7 mo (P =0.808), respectively. mRNA expression [21] ERCC1,
BRCA1
34 Gem+P The response rate in the RRM1-group was significantly greater than in the RRM1+ group (52.9% vs 5.9%, P=0.007).
Protein level [22] ERCC1, Protein level [24] overexpression of ribonucleotide reductase regulatory subunit M1 
